Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells

Carcinogenesis

Volumn 28, Issue 12, 2007, Pages 2521-2529

  Lin, Feng Min ^a   Chen, Li Ru ^a   Lin, En Hau ^a,b   Ke, Ferng Chun ^b   Chen, Hsin Yi ^a   Tsai, Meng Jen ^b   Hsiao, Pei Wen ^a  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; APIGENIN; INDOLE 3 CARBOXYALDEHYDE; INDOLE DERIVATIVE; LUTEOLIN; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; WEDELIA CHINENSIS EXTRACT; WEDELOLACTONE;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG STRUCTURE; GROWTH INHIBITION; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE INHIBITION; HUMAN; HUMAN CELL; MALE; MEDICINAL PLANT; ORIENTAL MEDICINE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TRANSCRIPTION INITIATION; WEDELIA; WEDELIA CHINENSIS;

ANDROGEN ANTAGONISTS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APIGENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; DRUG SYNERGISM; HUMANS; INDOLES; LUTEOLIN; MALE; NEOPLASMS, HORMONE-DEPENDENT; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; WEDELIA;

EID: 36949025979     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm137     Document Type: Article

References (45)

1. Jemal,A. et al. (2006) Cancer statistics, 2006. CA Cancer J. Clin., 56, 106-130.
2. Heinlein,C.A. et al. (2004) Androgen receptor in prostate cancer. Endocr. Rev., 25, 276-308.
3. Henderson,B.E. et al. (2000) Hormonal carcinogenesis. Carcinogenesis, 21, 427-433.
4. Balk,S.P. et al. (2003) Biology of prostate-specific antigen. J. Clin. Oncol., 21, 383-391.
5. Huang,W. et al. (1999) Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J. Biol. Chem., 274, 25756-25768.
6. De Marzo,A.M. et al. (2003) Human prostate cancer precursors and pathobiology. Urology, 62, 55-62.
7. Zhu,P. et al. (2006) Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124, 615-629.
8. Baron,J.A. et al. (2000) Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med., 51, 511-523.
9. Ho,E. et al. (2004) Dietary influences on endocrine-inflammatory interactions in prostate cancer development. Arch. Biochem. Biophys. 428, 109-117.
10. Craig,W.J. (1997) Phytochemicals: Guardians of our health. J. Am. Diet. Assoc., 97, S199-S204.
11. Craig,W.J. (1999) Health-promoting properties of common herbs. Am. J. Clin. Nutr., 70, 491S-499S.
12. Boon,H. et al. (2003) Use of complementary/alternative medicine by men diagnosed with prostate cancer: Prevalence and characteristics. Urology, 62, 849-853.
13. Zimmerman,R.A. et al. (2002) Prevalence of complementary medicine in urologic practice. A review of recent studies with emphasis on use among prostate cancer patients. Urol. Clin. North Am., 29, 1-9, vii.
14. JengM.Y.C. et al. (1998) Chinese Medicinal Plants. Reader's Digest Association Far East Ltd, Shaukiwan, Hong Kong.
15. Krishnaraju,A.V. et al. (2005) Assessment of bioactivity of Indian medicinal plants using brine shrimp (Artemia salina) lethality assay. Int. J. Appl. Sci. Eng., 3, 125-134.
16. Lin,S.C. et al. (1994) Hepatoprotective effects of Taiwan folk medicine: Wedelia chinensis on three hepatotoxin-induced hepatotoxicity. Am. J. Chin. Med., 22, 155-168.
17. Chou,T.C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev., 58, 621-681.
18. Sramkoski,R.M. et al. (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell. Dev. Biol. Anim., 35, 403-409.
19. Attardi,B.J. et al. (2004) Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol. Cell. Endocrinol., 222, 121-132.
20. Nakajima,E. et al. (2002) Isolation and identification of lateral bud growth inhibitor, indole-3-aldehyde, involved in apical dominance of pea seedlings. Phytochemistry, 61, 863-865.
21. Li,C.C. et al. (2003) Total synthesis of wedelolactone. J. Org. Chem., 68, 8500-8504.
22. Christophoridou,S. et al. (2005) Separation and identification of phenolic compounds in olive oil by coupling high-performance liquid chromatography with postcolumn solid-phase extraction to nuclear magnetic resonance spectroscopy (LC-SPE-NMR). J. Agric. Food Chem. 53, 4667-4679.
23. Mukherjee,A.K. et al. (2001) Advances in cancer therapy with plant based natural products. Curr Med. Chem., 8, 1467-1486.
24. Brusselmans,K. et al. (2005) Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J. Biol. Chem., 280, 5636-5645.
25. Fang,J. et al. (2007) Luteolin inhibits insuhn-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis, 28, 713-723.
26. Shukla,S. et al. (2005) Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J., 19 2042-2044.
27. Shukla,S. et al. (2004) Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: Correlation with down-regulation of NF-kappaB-responsive genes. Clin. Cancer Res., 10, 3169-3178.
28. Shukla,S. et al. (2006) Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol. Cancer Ther., 5, 843-852.
29. Kobori,M. et al. (2004) Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ., 11, 123-130.
30. Syrovets,T. et al. (2005) Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J. Biol. Chem., 280, 6170-6180.
31. Palayoor,S.T. et al. (1999) Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene, 18, 7389-7394.
32. Perkins,N.D. (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol., 8, 49-62.
33. Anderton,M.J. et al. (2004) Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin. Cancer Res., 10, 5233-5241.
34. Bhuiyan,M.M. et al. (2006) Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res., 66, 10064-10072.
35. Le,H.T. et al. (2003) Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J. Biol. Chem., 278, 21136-21145.
36. Chinni,S.R. et al. (2002) Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin. Cancer Res. 8, 1228-1236.
37. Hsu,J.C. et al. (2006) Indole-3-carbinol mediated cell cycle arrest of LNCaP human prostate cancer cells requires the induced production of activated p53 tumor suppressor protein. Biochem. Pharmacol, 72, 1714-1723.
38. Chinni,S.R. et al. (2001) Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene, 20, 2927-2936.
39. Takada,Y. et al. (2005) Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood, 106, 641-649.
40. Hougee,S. et al. (2005) Decreased pro-inflammatory cytokine-production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem Pharmacol. 69, 241-248.
41. Kumazawa,Y. et al. (2006) Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha. Curr. Pharm. Des., 12, 4271-4279.
42. Knowles,L.M. et al. (2000) Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer 38, 116-122.
43. Nelson,W.G. et al. (2001) Prostate cancer prevention agent development criteria and pipeline for candidate chemoprevention agents. Urology, 57, 56-63.
44. Singh,R.P. et al. (2006) Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat. Cancer, 13, 751-778.
45. Liu,R.H. (2004) Potential synergy of phytochemicals in cancer prevention: Mechanism of action. J. Nutr., 134, 3479S-3485S.